Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-Current Debt (2019 - 2025)

Historic Non-Current Debt for Puma Biotechnology (PBYI) over the last 7 years, with Q2 2025 value amounting to $10.9 million.

  • Puma Biotechnology's Non-Current Debt fell 7514.81% to $10.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.9 million, marking a year-over-year decrease of 7514.81%. This contributed to the annual value of $21.7 million for FY2024, which is 6692.15% down from last year.
  • As of Q2 2025, Puma Biotechnology's Non-Current Debt stood at $10.9 million, which was down 7514.81% from $10.6 million recorded in Q1 2025.
  • Over the past 5 years, Puma Biotechnology's Non-Current Debt peaked at $98.6 million during Q1 2023, and registered a low of $10.6 million during Q1 2025.
  • For the 5-year period, Puma Biotechnology's Non-Current Debt averaged around $68.5 million, with its median value being $76.5 million (2021).
  • As far as peak fluctuations go, Puma Biotechnology's Non-Current Debt surged by 4217.39% in 2022, and later tumbled by 8053.24% in 2025.
  • Quarter analysis of 5 years shows Puma Biotechnology's Non-Current Debt stood at $97.1 million in 2021, then increased by 1.25% to $98.3 million in 2022, then crashed by 33.21% to $65.7 million in 2023, then plummeted by 66.92% to $21.7 million in 2024, then plummeted by 49.96% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q2 2025, $10.6 million for Q1 2025, and $21.7 million during Q4 2024.